-Lean muscle gain

-Increases strength

-Potent adjunct therapy


-Reduces prostate size

-Formulated to replace TRT therapy

-Increases pumps



*NOTE: The thick consistency is normal. We do not use an ethanol base as it can become hepatoxic with prolonged use.


RAD-140 is an investigational selective androgen receptor modulator (SARM) developed as a future substitute of exogenous Testosterone replacement therapy (TRT)


RAD140 was discovered and initially developed by Radius Health, Inc. (RDUS). The first-in-human study was initiated in 2017 in patients with breast cancer. It was licensed to Ellipses Pharmaceuticals in 2020.


Interestingly RAD-140 reduces sex hormone binding globulin (SHBG), which has the consequence of increasing free-circulating testosterone counts. Not only does this bode well for increasing lean muscle mass and reducing body fat levels, clinical trials demonstrated that a higher free testosterone index was associated with better scores on visual and verbal memory, visuospatial functioning, visual-motor scanning and a reduced rate of longitudinal decline in visual memory. Therefore, RAD-140 becomes a potent anti-neurodegenerative adjunct therapy for those suffering Alzheimers.


RAD-140 has also been studied in patients with breast cancer. RAD140 is a potent AR agonist in breast cancer cells with a distinct mechanism of action, including the AR-mediated repression of ESR1. It inhibits the growth of multiple AR/ER+ breast cancer PDX models as a single agent, and in combination with palbociclib.


RAD-140 is typically used as a lean bulking agent, or for those seeking an alternative compound to testosterone in order to circumvent the side effects typically associated with that drug.


There are no reviews yet.

Be the first to review “Radolone”

Your email address will not be published. Required fields are marked *